Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05743972
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-02-24
First Post:
2023-02-15
Brief Title:
Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases Prospective Multicenter Randomized Controlled Trial
Sponsor:
xiao-yan xie
Organization:
First Affiliated Hospital Sun Yat-Sen University
Study Overview
Official Title:
Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases Prospective Multicenter Randomized Controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to previous studies contrast-enhanced ultrasound CEUS -guided Core BiopsyGB could improve the diagnosis of biopsy in liver and other superficial mass compared to conventional US-GB The purpose of this randomized trial is to estimate whether CEUS-GB achieve excellent diagnostic value to conventional US-GB in percutaneous biopsy for pancreatic diseases
Detailed Description:
The patients with pancreatic diseases who need receive percutaneous biopsy were randomized with 11 ratio into undergo CEUS-GB group and conventional US-GB groupThe aims include
Comparison the diagnostic accuracy rate between CEUS and US group Comparison the diagnostic specificity sensitivity and complication rate between CEUS and US group
Comparison the diagnostic accuracy rate between CEUS and US group Comparison the diagnostic specificity sensitivity and complication rate between CEUS and US group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None